Effects of the Tumor Necrosis Factor-α Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis | Zendy

Robert Bissonnette | Zendy; JeanClaude Tardif | Zendy; François Harel | Zendy; Joséphine Pressacco | Zendy; Chantal Bolduc | Zendy; MarieClaude Guertin | Zendy

Open Access

Effects of the Tumor Necrosis Factor-α Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With Psoriasis

Author(s) -

Robert Bissonnette,

JeanClaude Tardif,

François Harel,

Joséphine Pressacco,

Chantal Bolduc,

MarieClaude Guertin

Publication year - 2012

Publication title -

circulation cardiovascular imaging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.584

H-Index - 99

eISSN - 1942-0080

pISSN - 1941-9651

DOI - 10.1161/circimaging.112.975730

Subject(s) - medicine , adalimumab , psoriasis , positron emission tomography , clinical endpoint , cardiology , randomized controlled trial , nuclear medicine , tumor necrosis factor alpha , dermatology

Psoriasis is a chronic inflammatory disease associated with increased risks of myocardial infarction and stroke. Systemic treatments for moderate to severe psoriasis can reduce skin and joint inflammation; however, their effects on vascular inflammation are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research